Back to Clinical Trials

Brief Title: UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC)

A Phase 3b, Open-Label, Single-Arm, Multicenter Study to Assess the Feasibility of Home Instillation of UGN-102 for Treatment of Patients With Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence

INTRODUCTION

  • Org Study ID: BL010
  • Secondary ID: N/A
  • NTC ID: NCT05136898
  • Sponsor: UroGen Pharma Ltd.

BRIEF SUMMARY

This study aims to demonstrate that home instillation of UGN-102 is a feasible alternative to instillation in a clinical setting, which might mitigate some of the challenges in the patient experience (logistical, expense, and comfort) when receiving treatment for low-grade non-muscle-invasive bladder cancer at intermediate risk of recurrence (LG IR NMIBC).

  • Overall Status
    Recruiting
  • Start Date
    November 30, 2021
  • Phase
    Phase 3
  • Study Type
    Interventional

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Incidence of treatment-emergent adverse events (TEAEs), serious TEAEs, TEAEs of special interest, discontinuations from at home study treatment, and abnormal clinical laboratory tests (hematology, serum chemistry, and urinalysis).

Primary Outcome 1 - Timeframe: up to 3 months

Primary Outcome 2 - Measure: Feasibility questionnaires

Primary Outcome 2 - Timeframe: up to 3 months

CONDITION

  • Bladder Cancer
  • Urothelial Carcinoma
  • Urothelial Carcinoma Bladder

ELIGIBILITY

Inclusion Criteria:
Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and the protocol.

- Patient who has newly diagnosed or historic LG NMIBC (Ta) histologically confirmed by cold cup biopsy at Screening or within 8 weeks before Screening.
Has IR disease, defined as having 1 or 2 of the following:
presence of multiple tumors.

- solitary tumor > 3 cm.

- recurrence (≥ 1 occurrence of LG NMIBC within 1 year of the current diagnosis at the initial Screening Visit).

- Negative voiding cytology for high-grade (HG) disease within 6 weeks before Screening.
Has adequate organ and bone marrow function as determined by routine laboratory tests as below:
Leukocytes ≥ 3,000/μL (≥ 3×10^9/L).

- Absolute neutrophil count ≥ 1,500/μL (≥ 1.5×10^9/L).

- Platelets ≥ 100,000/μL (≥ 100×10^9/L).

- Hemoglobin ≥ 9.0 g/dL.

- Total bilirubin ≤ 1.5 × upper limit of normal (ULN).

- Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) ≤ 2.5 × ULN.

- Alkaline phosphatase (ALP) ≤ 2.5 × ULN.

- Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min.

- Has no evidence of active urinary tract infection (UTI) at the Screening and baseline visits.

- Patient is willing to receive instillations of UGN-102 at home (ie, Treatment Visits 2 to 6) by an appropriately trained home health professional.

- Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for clinical study participants. Women of childbearing potential (defined as premenopausal women who have not been sterilized), including female patients and female partners of male patients, must be willing to use 2 acceptable forms of effective contraception from first instillation through 6 months post treatment. Acceptable methods of birth control that are considered to have a low failure rate (ie, less than 1% per year) when used consistently and correctly include implants, injections, combined (estrogen/progesterone) oral contraceptives, intrauterine devices (only hormonal), condoms with spermicide, sexual abstinence, or vasectomized partner.

- Has an anticipated life expectancy of at least the duration of the trial.
Exclusion Criteria:
Received Bacillus Calmette-Guérin (BCG) treatment for urothelial carcinoma (UC) within previous 1 year.

- History of HG bladder cancer (papillary or carcinoma in situ) in the past 2 years.

- Known allergy or sensitivity to mitomycin that in the Investigator's opinion cannot be readily managed.

- Clinically significant urethral stricture that would preclude passage of a urethral catheter.
History of:
neurogenic bladder.

- active urinary retention.

- any other condition that would prohibit normal voiding.

- Past or current T1 UC, muscle invasive UC (ie, T2, T3, T4), metastatic UC, or concurrent upper tract urothelial carcinoma (UTUC).

- Has an underlying substance abuse or psychiatric disorder such that, in the opinion of the Investigator, the patient would be unable to comply with the protocol.

- History of prior treatment with an intravesical chemotherapeutic agent in the past 2 years except for a single dose of chemotherapy immediately after any previous transurethral resection of bladder tumors (TURBT).

- Has participated in a study with an investigational agent or device within 30 days of enrollment.

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Barbara Wamil, MD

Role: Study Director

Affiliation: UroGen Pharma

Overall Contact

Name: Barbara Wamil, MD

Phone: 646-809-2657

Email: christine.lentowski@urogen.com, evan.kiel@urogen.com

LOCATION

Facility Status Contact
Facility: Urology Centers of Alabama (UCA)
Homewood, Alabama 35209
United States
Status: Recruiting Contact: Contact
Vincent M Bivins, MD

vbivins@urologyal.com
Facility: Medication Management
Greensboro, North Carolina 27408
United States
Status: Recruiting Contact: Principal Investigator
VIncent M Bivins, MD

judy.branson@emailmm.com
Facility: Urology Associates, P.C.
Nashville, Tennessee 37209
United States
Status: Recruiting Contact: Contact
Judy Branson

dsmorris@ua-pc.com
Facility: Virginia Urology
Richmond, Virginia 23235
United States
Status: Recruiting Contact: Principal Investigator
Theodore Manny, MD

ekramolowsky@uro.com